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Abstract
Background: We sought to explore the association of variant rs1333049 on chromosome 9p21.3 with coronary
artery disease (CAD) and angiographic plaque progression in non-diabetic and type 2 diabetic patients.
Methods: Genotyping and quantitative coronary angiography (QCA) were performed in 2046 Chinese Han patients
(1012 diabetic cases) undergoing coronary angiography; 430 of them received repeat angiographic studies at
1-year follow-up.
Results: CC genotype at rs1333049 on chromosome 9p21.3 was associated with CAD (unadjusted OR 1.524,
p = 0.001 and adjusted OR 1.859, p = 0.005, respectively). However, CC genotype had no magnified association
with CAD in diabetic patients (OR 1.275, p = 0.150) compared with non-diabetic counterparts (OR 1.446, p = 0.020)
after adjusting for conventional risk factors. During angiographic follow-up, non-diabetic patients (n = 280) had
significant decrease in minimal lumen diameter and increase in percent diameter stenosis among the three
genotypes (p = 0.005 and p = 0.038, respectively), demonstrating that CC or GC genotype carriers had a more
severe plaque progression than GG genotype carriers. In patients with type 2 diabetes (n = 150), although plaque
progression was more severe than that in non-diabetic counterparts, no relations existed between plaque
progression and genotypes. Rs1333049 was an independent determinant of plaque progression for non-diabetic
(OR 3.468, p = 0.004 and OR 4.339, p = 0.002 for GC and CC genotype, respectively) but not for diabetic patients
(OR 0.529, p = 0.077 and 0R 0.878, p = 0.644 for GC and CC genotype, respectively).
Conclusions: This study demonstrates a significant association of homozygous CC genotype of rs1333049 on
chromosome 9p21.3 with CAD in Chinese Han population. Rs1333049 polymorphism is an independent
determinant for coronary plaque progression in non-diabetic but not in type 2 diabetic patients.
Background
Recent genome-wide scanning has implicated chromo-
some 9p21.3 as a novel locus conferring susceptibility to
coronary artery disease (CAD), myocardial infarction
and cardiac death [1-5], which is independent of tradi-
tional risk factors including gender, age, obesity, smok-
ing, hypertension and hyperlipidemia [6,7]. Several
studies showed that chromosome 9p21.3 was a vital
genetic region with different independent loci of SNPs
related to either diabetes or CAD [8-11]. The risk of
CAD associated with 9p21 variant was increased in the
presence of poor glycemic control in type 2 diabetes [8].
Also, as one of the risk equivalents of CAD, patients
with diabetes often had an increased atherosclerotic bur-
den and inflammatory process in the coronary artery
tree [12-14]. Thus, we hypothesized that certain locus
on chromosome 9p21.3 might have its effect in a com-
mon pathway of diabetes and CAD. In a recent study,
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atherosclerotic plaque progression and polymorphism
on chromosome 9p21.3 in Caucasian population [15].
Admittedly, this cross-section study was not designed to
seek possible association of 9p21.3 with CAD in a spe-
cial diabetic population. Furthermore, genetic effect of
variant rs1333049 on chromosome 9p21.3 on angio-
graphic coronary disease progression in Chinese patients
remains unclear. Therefore, the present case-control
study was conducted to examine whether this locus
influences angiographic pla q u ep r o g r e s s i o ni nC h i n e s e
Han non-diabetic and type 2 diabetic patients.
Methods
Patients
The study protocol was approved by the hospital Ethics
Committee, and written informed consents were
obtained from all subjects.
The study population consisted of 2046 Chinese Han
patients (1012 diabetic and 1034 non-diabetic cases)
undergoing coronary angiography between March 2004
and December 2007 for the evaluation of suspected or
established CAD (luminal diameter narrowing ≥50%); 430
of them received repeat angiography at 1-year follow-up.
Type 2 diabetes was defined as a fasting plasma glucose
level ≥7.0 mmol/L or non-fasting plasma glucose
level≥11.1 mmol/L, or taking oral hypoglycemic drugs or
receiving parenteral insulin therapy. Patients with type 1
diabetes were excluded by measuring C peptide, and
excluded were also those with chronic viral or bacterial
infection, tumor, or immune system disorders. Diagnosis
of hypertension was based on the presence of elevated sys-
tolic (≥140 mmHg) and/or diastolic (≥90 mmHg) blood
pressure, or current use of antihypertensive medications
for one year before admission. Patients were diagnosed as
hyperlipidemia if serum levels of total cholesterol (TC)
>5.7 mmol/l (220 mg/dl), triglycerides (TG) >1.7 mmol/l
(150 mg/dl), low-density lipoprotein cholesterol (LDL-C)
>3.64 mmol/L (140 mg/dl), or high-density lipoprotein
cholesterol (HDL-C) <0.91 mmol/L (35 mg/dl).
Coronary angiography and quantitative analysis
Coronary angiography was performed using standard
Judkins techniques or through radial approach, and all
major coronary arteries were carefully imaged on at least
two orthogonal views. Quantitative coronary analysis
(QCA) was performed (TERRA, GE, USA) by two experi-
enced interventional cardiologists, who were unaware of
clinical information of the patients. For those with coron-
ary angiography at baseline and 1-year follow-up, all cor-
onary arteries intervened with percutaneous coronary
intervention (PCI) were excluded to avoid inclusion of
post-PCI neointimal hyperplasia or restenosis [16]. The
coronary artery segments analyzed included all those
plaques with a reference diameter ≥ 1.5 mm and a steno-
sis ≥ 20% at baseline and those with new lesions at fol-
low-up in non-PCI intervened artery. Using the outer
diameter of the contrast-filled catheter as the calibration,
the minimal lumen diameter (MLD) in diastole was mea-
sured from multiple projections. Atherosclerotic plaque
progression was diagnosed if one of the following criteria
was met: (1) ≥10% diameter reduction of a pre-existing
stenosis ≥50%; (2) ≥30% diameter reduction of a stenosis
<50%; (3) progression of any stenosis to total occlusion,
or (4) development of a new stenosis ≥30% in a pre-
viously normal segment [17]. A new coronary lesion was
defined as a stenosis that was not apparent on the initial
angiogram or was <20% in diameter stenosis but that
narrowed by≥0.4 mm in MLD at the follow-up angio-
gram [18]. Coronary artery score was calculated from
per-patient average of the MLD of all the measured seg-
ments in observed coronary artery, and cumulative cor-
onary obstruction was the sum of all percent diameter
stenosis in standard index unit (50% = 0.50) [19]. Change
of QCA measurements was defined as baseline QCA
measurement minus follow-up measurement.
Biochemical investigation
Blood samples were collected after an overnight fasting in
all patients and were stored at -80°C. Serum glucose,
hemoglobin A1c (HbA1c), insulin levels, blood urea nitro-
gen (BUN), creatinine, and lipid profiles (TC,LDL-C,
HDL-C,TG) were measured (HITACHI 912 Analyzer,
Roche Diagnostics, Germany). Serum high sensitivity
C-reactive protein (hsCRP) level was determined using a
high-sensitivity ELISA kit (Biocheck Laboratories, Toledo,
OH, USA) with a linear range of 0.62-119.3 mg/L and an
inter-assay CV <7.5%.
Genotyping
Genomic DNA was extracted from peripheral blood leu-
cocytes by standard phenol-chloroform extraction. Gen-
otyping was performed with TaqMan SNP allelic
discrimination by means of an ABI 7900HT (Applied
Biosystems, Foster City, CA, USA), in 384-well format.
The TaqMan Assay kit was purchased from Applied
Biosystems (Foster City, CA, USA). Genotypes were
determined with the same method as previously
described [20], in which primers of rs1333049 poly-
morphism were TCACTACCCTACTGTCATTCCTCAT
and TTGCTTACCTCTGCGAGTGG, and probes were
VIC-CAACAGTTCAAAAGCA and FAM-AACAGTT-
GAAAAGCA. Data were analyzed using the ABI Prism
SDS software version 2.1.
Statistical analysis
Continuous variables are presented as mean ± standard
deviation, and categorical data are summarized as
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tinuous variable was evaluated with Kolmolgorov-Smir-
nov test. For categorical variables, differences between
groups were evaluated by the chi-square test. Differ-
ences among genotypes were analyzed by one-way ana-
lysis of variance (ANOVA) followed by post-hoc analysis
(Bonferroni’s correction) for comparison between
groups. Odds ratios (ORs) of CAD were first estimated
by chi-square test and then adjusted by traditional risk
factors for CAD including gender, age, hypertension,
hyperlipidemia, smoking status and diabetes (all factors
with p < 0.05 between CAD and non-CAD in the study
population). ORs of covariates determining plaque pro-
gression were estimated using a multivariable logistic
regression model. A 2-sided probability level of ≤0.05
was considered significant. All analyses were done with
SPSS for Windows 13.0 (SPSS Inc, Chicago, Illinois,
USA).
Results
Baseline characteristics of the study population
As expected, patients with CAD were older and more
male gender, and had more risk factors for CAD includ-
ing smoking, hypertension, hyperlipidemia and diabetes
and higher serum hsCRP level than those without CAD
(all p < 0.05; data not shown). Despite similar medical
treatments, patients with plaque progression had more
diabetes, elevated serum levels of 2 h plasma glucose
a n dh s C R P ,a n dr e d u c e dH D L - Ct h a nt h o s ew i t h o u t
plaque progression (Table 1).
Association between rs1333049 polymorphism and CAD
The genotype frequencies of rs1333049 were in Hardy-
Weinberg equilibrium in patients with and without
CAD (all p > 0.05, data not shown). CC genotype of
rs1333049 was associated with CAD in overall patients
with unadjusted OR 1.524, 95% CI 1.192-1.949,
p = 0.001 and adjusted OR 1.859, 95% CI 1.212-2.852,
p = 0.005, respectively (Table 2). Further analysis
showed that CC genotype was not significantly asso-
ciated with CAD in diabetic patients (OR 1.275, 95% CI
0.843-1.930, p = 0.150) compared with non-diabetic
counterparts (OR 1.446 95% CI 1.145-1.826, p = 0.020).
Association between rs1333049 polymorphism and
plaque progression
Biochemical measurements and angiographic features
with respect to various genotypes are listed in Table 3.
White blood cell (WBC) and neutrophile counts were
significantly higher in CC genotype carriers. There were
no significant differences in changes of MLD, percent
diameter stenosis and number of new coronary lesions
among the three genotypes in the whole population at
follow-up angiography (all p > 0.05) (Table 3). In non-
diabetic patients, risk C allele of rs1333049 was related
to degree of MLD reduction (0.25 ± 0.49 mm for CC
genotype, 0.20 ± 0.35 mm for GC genotype, and 0.05 ±
0.35 mm for GG genotype, respectively, p = 0.005)
(Table 4). Similar findings were observed for change of
percent diameter stenosis, coronary artery score and
cumulative coronary obstruction (p = 0.038, 0.004 and
0.025, respectively). Although diabetic patients had more
severe plaque progression than non-diabetic counter-
parts, no relations existed between plaque progression
and genotypes (all p > 0.05) (Table 4).
Determinants of plaque progression
Multivariable logistic regression analysis revealed that gen-
der (male), hypertension, genotypes carrying allele C, low
HDL-C and high hsCRP were independently associated
with plaque progression in non-diabetic patients during 1-
year follow-up (OR 3.468 95% CI 1.504-8.000, p = 0.004
for GC genotype and OR 4.339 95% CI 1.740-10.821, p =
0.002 for CC genotype). Meanwhile, gender (male), age,
hyperlipidemia, smoking and high hsCRP, but not risk
genotype of rs1333049, were independent determinants of
plaque progression in diabetic patients (Table 5).
Discussion
This study demonstrates that SNP of rs1333049 on
chromosome 9p21.3 increases the susceptibility to CAD
in Chinese Han population and confers a magnified risk
of coronary plaque progression in non-diabetic patients.
Several genome-wide association studies have shown
that different genetic variations on chromosome 9p21.3
were associated with increased risk of diabetes, CAD and
sudden cardiac death in the general population [2,8-10].
As one of the risk equivalents of CAD, diabetes increased
atherosclerotic burden and inflammatory process in the
coronary artery tree [12-14]. Doria et al reported an
interaction between poor glycemic control and 9p21
locus on risk of CAD in type 2 diabetes [8]. However, we
observed that homozygous CC genotype of rs1333049
was not strongly associated with CAD in diabetic popula-
tion in this study, which was in accordance with the find-
ings from a prospective meta-analysis that no interaction
existed between diabetes and rs1333049 polymorphism
in CAD development [7]. Similarly, there was a magnified
risk of C allele for coronary plaque progression in non-
diabetic but not in diabetic patients, implying that poly-
morphism on chromosome 9p21 might have effects on
CAD development in a novel biological pathway other
than interaction with diabetes or glucose metabolism.
Genetic variation on chromosome 9p21 has been
reported to be associated with progression of carotid but
not coronary atherosclerosis in Caucasian population
[15,21]. Besides, specific polymorphisms in the chromo-
some 9p21.3 region that were shown to be associated
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to clinical and angiographic outcomes after implantation
of drug-eluting stents in the coronary arteries [22]. Thus,
this study was the first to show an association of SNP on
chromosome 9p21.3 with CAD and angiographic plaque
progression in a special population. In addition, variant at
chromosome 9p21 was associated with recurrent myocar-
dial infarction and cardiac death after acute coronary
syndrome, serving as a predictive factor of perioperative
myocardial injury after coronary artery bypass graft sur-
gery [23,24]. Taken together, this genetic factor might
partially increase the risk of CAD by promoting athero-
sclerosis development or plaque instability.
T h eh i g hr i s ko fh a p l o t y p ea t9 p 2 1 . 3w a ss h o w nt o
overlap with exons 13 to 19 of ANRIL [25-28], which
was expressed in atheromatous plaques and served as a
Table 1 Baseline clinical characteristics and biochemical assessments of plaque progression study
CAD
Plaque Progression
(n = 137)
No Plaque Progression
(n = 293)
P
Men/Female (n) 97/40 208/85 0.864
Age (years) 64.13 ± 7.80 65.51 ± 10.13 0.299
Cigarette smoking (%) 61(44.5%) 139(47.4%) 0.604
Hypertension (%) 65 (47.4%) 130 (44.4%) 0.512
Hyperlipidemia (%) 36 (26.3%) 65 (22.1%) 0.466
Diabetes (%) 69 (43.0%) 81 (28.0%) 0.033
BMI (kg/m
2) 24.63 ± 3.46 24.05 ± 3.24 0.189
Fasting plasma glucose (mmol/L) 5.49 ± 1.88 5.99 ± 2.00 0.255
2 h plasma glucose (mmol/L) 13.40 ± 4.20 11.29 ± 3.66 0.039
HbA1c (%) 6.79 ± 1.48 6.64 ± 1.43 0.315
hsCRP (mg/ml) 19.35 ± 13.63 11.87 ± 9.22 <0.001
Total cholesterol (mmol/L) 4.77 ± 1.04 4.84 ± 1.16 0.631
Triglyceride (mmol/L) 1.93 ± 1.53 2.02 ± 1.32 0.319
LDL-C (mmol/L) 2.80 ± 0.79 2.84 ± 0.85 0.672
HDL-C (mmol/L) 1.09 ± 0.31 1.27 ± 0.27 0.015
apoA (g/L) 1.22 ± 0.20 1.27 ± 0.22 0.156
apoB (g/L) 0.97 ± 0.22 0.95 ± 0.23 0.674
Lipoprotein (a) (g/L) 0.25 ± 0.18 0.23 ± 0.16 0.422
BUN (mmol/L) 5.49 ± 1.89 5.88 ± 1.65 0.078
creatinine (mg/L) 91.51 ± 23.16 89.78 ± 20.08 0.534
Statin (%) 126 (92.1%) 262 (89.5%) 0.475
ACEI or ARB (%) 114 (83.3%) 231 (79.0%) 0.285
b-blocker (%) 59 (43.1%) 121 (50.9%) 0.448
Antiplatelet (%) 123 (90.1%) 215 (90.3%) 0.656
Insulin (%) 36 (26.2%) 30 (12.7%) 0.069
Oral anti-diabetic drugs (%) 49 (35.7%) 111 (46.5%) 0.144
Data are number (%) and mean ± SD;
Abbreviations: CAD, coronary artery disease; BMI, body mass index; HbA1c, glycosylated hemoglobin; hsCRP, high sensitivity C-reactive protein; HDL-C, high-
density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; BUN, blood urea nitrogen.
Table 2 Multivariable analysis of independent determinants for coronary artery disease in the whole population
Variables Unadjusted OR (95% CI) p Adjusted OR (95% CI) p
Rs1333049 (GC vs. GG) 1.199 (0.966-1.487) 0.099 1.105 (0.755-1.619) 0.607
Rs1333049 (CC vs. GG) 1.524 (1.192-1.949) 0.001 1.859 (1.212-2.852) 0.005
Gender (male vs. female) 2.534 (2.132-3.011) <0.001 2.516 (2.107-3.224) <0.001
Age (years) 2.093 (1.760-2.489) <0.001 1.952 (1.627-2.341) <0.001
Hypertension (yes vs. no) 1.589 (1.347-1.875) <0.001 1.490 (1.251-1.774) <0.001
Hyperlipidemia (yes vs. no) 1.187 (0.952-1.473) 0.119 1.274 (1.008-1.608) 0.042
Smoking (yes vs. no) 2.242 (1.893-2.655) <0.001 1.837 (1.527-2.211) <0.001
Diabetes (yes vs. no) 1.873 (1.571-2.233) <0.001 1.780 (1.470-2.157) <0.001
Risk factors which are adjusted include gender, age, hypertension, hyperlipidemia, smoking status and diabetes.
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Rs1333049
GG (n = 122) GC (n = 200) CC (n = 108) p
Change of Biochemical measurements
Total cholesterol (mmol/L) 0.64 ± 1.17 0.41 ± 1.12 0.53 ± 1.14 0.228
LDL-C (mmol/L) 0.27 ± 0.98 0.24 ± 0.90 0.34 ± 0.86 0.623
HDL-C (mmol/L) -0.05 ± 0.49 -0.01 ± 0.22 0.01 ± 0.19
a 0.422
Triglyceride (mmol/L) 0.41 ± 1.92 0.10 ± 0.86
a 0.16 ± 1.06
b 0.106
apoA (g/L) 0.10 ± 0.15 0.09 ± 0.17 0.08 ± 0.16 0.029
apoB (g/L) 0.41 ± 0.37 0.39 ± 0.30 0.40 ± 0.34 0.639
Lipoprotein (a) (g/L) -0.01 ± 0.08 -0.02 ± 0.09 -0.01 ± 0.12 0.873
Fast glucose (mmol/L) 0.39 ± 1.22 0.42 ± 2.48 0.66 ± 1.58 0.487
HbA1c (%) 0.52 ± 1.54 0.40 ± 1.32 0.27 ± 1.44 0.419
White blood cells (× 10
9/L) 0.75 ± 2.02 0.92 ± 1.94
a 1.46 ± 1.87
a 0.012
Neutrophile (× 10
9/L) 0.51 ± 1.64 0.66 ± 1.98 1.13 ± 1.80
a 0.025
Lymphocyte (× 10
9/L) 0.21 ± 0.66 0.21 ± 0.64 0.29 ± 0.54 0.463
Smoking status
Non-smoker (%) 67 (54.9%) 109 (54.5%) 54 (49.2%) 0.309
Smoker with cessation (%) 30 (24.6%) 49 (24.5%) 30 (27.7%) 0.474
Smoker without cessation (%) 25 (20.5%) 42 (21.0%) 24 (23.1%) 0.532
Angiographic features
New coronary lesion 0.09 ± 0.29 0.07 ± 0.26 0.11 ± 0.32 0.385
Change of MLD (mm) 0.18 ± 0.46 0.26 ± 0.44 0.29 ± 0.50 0.151
Change of diameter stenosis (%) -5.14 ± 15.87 -8.82 ± 16.03 -9.38 ± 14.89 0.081
Coronary artery score (mm) 0.05 ± 0.03 0.16 ± 0.07 0.21 ± 0.11 0.188
Cumulative coronary obstruction -0.03 ± 0.09 -0.20 ± 0.13 -0.31 ± 0.21 0.076
MLD, minimal lumen diameter; other abbreviations are listed in table 1
a < 0.05 compared with GG
b <0.01 compared with GG
Table 4 Plaque progression in different genotypes of rs1333049
Non-DM (N = 280) GG (n = 90) GC (n = 114) CC (n = 76) p
New coronary lesion 0.05 ± 0.22 0.07 ± 0.27 0.11 ± 0.32 0.347
Change of MLD (mm) 0.05 ± 0.35 0.20 ± 0.35
a 0.25 ± 0.49
b 0.005
Change of diameter stenosis (%) -3.44 ± 13.80 -7.38 ± 13.70 -8.93 ± 14.64
a 0.038
Coronary artery score (mm) 0.01 ± 0.02 0.12 ± 0.04
a 0.16 ± 0.07
b 0.004
Cumulative coronary obstruction -0.02 ± 0.11 -0.17 ± 0.09 -0.28 ± 0.13
a 0.025
DM (N = 150) GG (n = 32) GC (n = 86) CC (n = 32)
New coronary lesion 0.19 ± 0.40 0.07 ± 0.23 0.13 ± 0.34 0.173
Change of MLD (mm) 0.34 ± 0.53 0.39 ± 0.53 0.46 ± 0.56 0.513
Change of diameter stenosis (%) -9.20 ± 19.61 -10.86 ± 18.77 -10.67 ± 15.74 0.908
Coronary artery score (mm) 0.14 ± 0.07 0.22 ± 0.11 0.29 ± 0.15 0.152
Cumulative coronary obstruction -0.05 ± 0.10 -0.25 ± 0.18 -0.36 ± 0.27 0.770
MLD, minimal lumen diameter.
a < 0.05 compared with GG
b <0.01 compared with GG
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mation [25,27]. And, variants on 9p21.3 had a role in
regulation of cardiac cyclin dependent kinase inhibitor
2A/2B (CDKN2A/2B) expression by altering the
dynamics of vascular cell proliferation [29]. As white
blood cells especially neutrophiles, an important cell line
in vascular inflammation, were significantly increased in
CC genotype carriers in this study, the relationship
between 9p21.3 and inflammation might be a possible
explanation for angiographic plaque progression. Further
functional analyses are needed to clarify possible path-
ways in which this SNP on chromosome 9p21.3 contri-
butes to development of CAD and plaque progression.
Although diabetic patients had more severe plaque
progression than non-diabetic counterparts, risk geno-
type of rs1333049 was not an independent determinant
of plaque progression in diabetes. The difference in
association between variant rs1333049 on chromosome
9p21.3 and plaque progression in diabetic and non-dia-
betic patients suggested that CAD in diabetes might be
mediated through a pathway other than polymorphism
on 9p21.3, and perhaps the role of other risk factors
exceeded that of variants on 9p21.3 in conferring more
severe plaque burden for diabetic patients.
This study had several limitations. First, all patients
received medical treatments during follow-up, which
could affect the natural course of the disease and plaque
progression. However, since patients with or without
plaque progression received similar medical treatment
which was listed in Table 1 and no significant change of
medical treatment was made before the result of the fol-
low-up angiography, these could help to decrease the
influence of treatment to certain extent. Second, case-
control studies had advantages for identifying disease
related genes, but they were limited to detect gene-
environment interactions [30]. A prospective cohort
study is needed to better illustrate the role of genetic
and environmental factors as well as their interactions
in CAD development.
Conclusions
Polymorphism on chromosome 9p21.3 is significantly
associated with CAD in Chinese Han population, and
also contributes to coronary plaque progression in non-
diabetic patients. Thus, SNP scanning on 9p21.3 should
been done to select the patients with potential risk of
CAD or angiographic plaque progression in non-diabetic
population. Early medical intervention or close follow-
up of non-diabetic patients with risk genotype is of
equal importance to primary or secondary prevention
for CAD in diabetes.
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